Fundraising Fox
Monograph Capital Partners
Venture capitalLondon · Seed–Series B · 21 people tracked
Also known as Monograph · Monograph Capital · MONOGRAPH CAPITAL ADVISORS (UK), LLP · MONOGRAPH CAPITAL ADVISORS, L.P.
Find your way into Monograph Capital Partners
Sign up to see every warm intro you have to Monograph Capital Partners
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Monograph Capital Partners team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Monograph Capital invests in innovative life sciences companies with the goal of turning promising science into life-changing treatments for patients worldwide. The firm operates as a transatlantic team focused on sourcing leading scientific innovation and supporting company development across geographic boundaries. It combines differentiated deal sourcing, long-standing relationships with pharmaceutical companies, deep medical expertise, and seasoned operating experience to build strong companies and create value for both company partners and investors, ultimately aiming to improve patient health outcomes over time.
Source: firm website, verified Sep 29, 2026.
Team · 21 people
from the firm's website & curated & public directories
Founder mafia
4 people who came through Monograph Capital Partners went on to found or lead other companies.
What they invest in
from 16 of 23 portfolio companiesBiotech ×14Healthtech ×11Medical Devices ×8Deep Tech ×3Digital Health ×3AI & Machine Learning ×2SaaS ×2Enterprise Software ×1
HQs:United States×7United Kingdom×3Germany×1
Who they back
founder profiles across 10 portfolio companiesFounding team size:solo founder×42 founders×43 founders×2
Where their founders worked beforefrom 11 founders with career history
King's College London ×2
Investments · 23 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 32024 · 22023 · 32022 · 212 dated
Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.
BiotechHealthtechMedical DevicesLondon, GB
Emma Tinsley(Founder & former CEO (now Non-Executive Director))inMai-Britt Zocca(CEO)in
Co-investorsSofinnova PartnersForbion
Maxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs.
BiotechHealthtechCambridge, GB
John McCafferty(Co-founder and CTO)inAneesh Karatt-Vellatt(Co-founder and CSO)inArndt Schottelius, MD, PhD(CEO)
Co-investorsGeneral CatalystLifeArc VenturesSolasta Ventures
.png)
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.
BiotechHealthtechMedical DevicesWatertown, US
MATTHEW FRANKEL(Executive Officer)inPETER COUROSSI(Executive Officer)RICHARD BATYCKY(President and Chief Executive Officer)JAMES ELLIS(Executive Officer)MICHAEL LIPP(Executive Officer)inCHRISTOPHER SILBER(Executive Officer)in
Board seatFreddie Dear· per SEC Form D
Co-investorsCanaan PartnersF-Prime CapitalLumira VenturesMission BiocapitalOUP (Osage University Partners)
Ascend is a gene-to-GMP development partner that helps life-science companies advance advanced therapy products from the research bench through clinical stages.
BiotechHealthtechMedical DevicesMunich, DE
Evis Hursever(Executive Officer)Wesley McConnell(Executive Officer)inMichael Stella(Executive Officer, Director)William Hawkins(Executive Officer)
BoardMichael Beecham(Director)Andrew Kozlov(Director)
Co-investorsCathay HealthDCVC (Data Collective)4BIO CapitalDigitalis Ventures
Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)inJohn Borkholder(Executive Officer)in
BoardKristina Burow(Director)inThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
Co-investorsARCH Venture PartnersCanaan PartnersPfizer Venture InvestmentsSamsara BioCapitalInsight PartnersNewpath Partners
AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
BiotechDeep TechDigital HealthHealthtech
Chris Shaw(Co-Founder & Chief Scientific and Clinical Advisor)inDo Young Lee(Co-Founder)Youn Bok Lee(Co-Founder)inLisa Deschamps(Chief Executive Officer)inGraeme Fielder(Chief Operating Officer)inAlex Bloom(Chief Development Officer)in
Co-investorsAdvent Life SciencesDementia DiscoveryF-Prime CapitalLifeArc VenturesNew Enterprise Associates (NEA)SV Health Investors
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin
Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLongitude CapitalLumira Ventures+5 more
Biotech company developing antibodies to treat autoimmune and inflammatory diseases.
Co-investorsAlpha Wave GlobalArkin CapitalArkin Digital HealthJeito CapitalViking GlobalARCH Venture Partners+1 more
ODAIA offers Marketing Intelligence, a platform for pharmaceutical marketing and sales teams that ties channel-level actions to prescription (Rx) outcomes and coordinates healthcare provider (HCP) engagement across digital and field channels.
AI & Machine LearningDigital HealthHealthtechMarketing TechSaaSSales Tech
Philip Poulidis(Founder)inHelen Kontozopoulos(Founder)
Co-investorsAlumni VenturesGraphite VenturesPanache VenturesStand Up VenturesThreshold VenturesToronto Innovation Acceleration Partners+5 more
Ollin Biosciences is a clinical-stage biopharmaceutical company that acquires and develops therapies for vision-threatening eye diseases, including wet age-related macular degeneration, diabetic macular edema, and thyroid eye disease.
BiotechMedical Devices
Co-investorsAndreessen HorowitzTCG Crossover
Ouro Medicines is a biotechnology company developing cell-depleting therapies aimed at resetting the immune system to treat chronic immune-mediated diseases such as autoimmune and autoinflammatory conditions.
BiotechHealthtechSouth San Francisco, US
Jaideep(Founding Chief Executive Officer)Neely Mozaffarian(Chief Medical Officer)inChristina(General Counsel & Chief Operating Officer)
Co-investorsNew Enterprise Associates (NEA)Norwest Venture PartnersTPG
Prolynx develops ultra-long-acting therapeutics for obesity and metabolic diseases such as type 2 diabetes, using a hydrogel-based microsphere platform with tunable release linker chemistry to control drug release over extended dosing intervals.
BiotechDeep Tech
Gary Ashley(Co-Founder)inDaniel Santi(Co-Founder)inChris Boulton(CEO)inSimon Harnest(Chief Financial Officer)inAmer Mirza(Chief Scientific Officer)inChristian Weyer(Chief Medical Officer)in
Co-investorsOrbiMed
RegASK provides an AI-native regulatory intelligence platform that monitors regulatory changes across 160+ markets, orchestrates compliance workflows, and pairs automation with a community of regulatory experts for validation.
AI & Machine LearningEnterprise SoftwareSaaS
Caroline Shleifer(Founder)in
RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.
BiotechHealthtech
Co-investorsFrazier Life SciencesLifeArc VenturesOxford Science EnterprisesWellington ManagementEQT Life SciencesForbion+1 more
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)inScott Byrd(Executive Officer, Director)in
Co-investorsFrazier Life SciencesPICUS CAPITALSanofi VenturesSV Health InvestorsDementia Discovery FundFrazier Healthcare Partners+2 more
UroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology.
BiotechHealthtechMedical DevicesPrinceton, US
Mark Schoenberg, M.D.(Executive Officer)Liz Barrett(President and Chief Executive Officer)inJason Smith(Executive Officer)Arie Belldegrun, M.D.(Director)Dan Wildman(Director)Don Kim(Executive Officer)
Co-investorsAisling CapitalPontifax Venture CapitalAravis Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ollin Biosciences, Inc.AscendAutobahnHuman Immunology BiosciencesMiroBioProlynxSudo
Exits · 2
2 acquisitions · showing 1HI-Bioacq. by Biogen
Portfolio news
latest coverage across their companiesRQ Bio · finsmes.com · Jun 24, 2026
Nocion Therapeutics · nociontx.com · Mar 20, 2026
Elevara · finsmes.com · Oct 23, 2025
Frequently asked questions
- How many investments has Monograph Capital Partners made?
- Monograph Capital Partners has 23 tracked investments, 2 of which have exited, including 6 dated in the last 24 months.
- What stage does Monograph Capital Partners invest at?
- Monograph Capital Partners invests at the Seed, Series A, Series B stages.
- What sectors does Monograph Capital Partners focus on?
- Monograph Capital Partners focuses on Biotech, Healthtech, Medical Devices.
- Where is Monograph Capital Partners located?
- Monograph Capital Partners is headquartered in London, GB.
- Does Monograph Capital Partners lead rounds?
- Yes, Monograph Capital Partners leads investment rounds.
- Who does Monograph Capital Partners co-invest with?
- Monograph Capital Partners most often shares deals with New Enterprise Associates (NEA), ARCH Venture Partners, Canaan Partners, among 48 tracked co-investors.
Images
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Blackbird is a venture capital firm that backs founders from the earliest stages, with a focus on ambitious technology startups across Australia and New Zealand.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.